TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1919373

Group type: EXPERIMENTAL
Intervention: Paraspinal skin temperature differential instrument
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: First observation between examiners
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Second observation between examiners
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intraexaminer agreement for one examiner
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intraexaminer agreement for the other examiner
Number of subjects: 19
Study: 6556391

Group type: EXPERIMENTAL
Intervention: Primary prevention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 29989964

Group type: EXPERIMENTAL
Intervention: Continuous 3D Label Stereo Matching using local expansion moves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional expansion moves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fusion moves or belief propagation
Number of subjects: 0
Study: 28599949

Group type: EXPERIMENTAL
Intervention: Quetiapine-ER (600 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Aripiprazole (20 mg/day)
Number of subjects: 113
Study: 26138780

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 16
Study: 23561069

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction group
Number of subjects: 10
Study: 20632462

Group type: EXPERIMENTAL
Intervention: Oral estradiol therapy (ET)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 18198413

Group type: EXPERIMENTAL
Intervention: 2 min occlusion during high estrogenic phase
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 min occlusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1, 2, or 3 min occlusion
Number of subjects: 120
Study: 16338502

Group type: EXPERIMENTAL
Intervention: Assessment and case management for 6 months (treatment group)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Written list of services (control group)
Number of subjects: 188
Study: 15505445

Group type: EXPERIMENTAL
Intervention: sevoflurane‐remifentanil (</= 0.1 microg . kg . min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: sevoflurane‐remifentanil (>/= 0.2 microg . kg . min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: propofol‐remifentanil (</= 0.1 microg . kg . min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: propofol‐remifentanil (>/= 0.2 microg . kg . min)
Number of subjects: 40
Study: 10706965

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/B vaccine
Number of subjects: 282

Group type: COMPARATOR
Intervention: Monovalent hepatitis B vaccine
Number of subjects: 282
Study: 9085952

Group type: EXPERIMENTAL
Intervention: 5 IU of oxytocin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 IU of oxytocin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 15 IU of oxytocin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 IU of oxytocin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (5, 10, 15, 20 IU of oxytocin)
Number of subjects: 40
Study: 8227917

Group type: EXPERIMENTAL
Intervention: Walking group (exercised at 60% heart rate reserve for 30 to 40 minutes, 5 days a week for 12 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Calisthenic group (engaged in mild range-of-motion and flexibility movements for 30 to 40 minutes, 5 days a week for 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Highly conditioned elderly women (cross-sectional comparison)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sedentary elderly women (baseline comparison)
Number of subjects: 32
Study: 3754834

Group type: EXPERIMENTAL
Intervention: Defibrotide (800 mg daily, 200 mg intravenously 4 times a day for 7 days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 2450026

Group type: EXPERIMENTAL
Intervention: sotalol 160 mg b.d.
Number of subjects: 103

Group type: COMPARATOR
Intervention: atenolol 50 mg b.d.
Number of subjects: 103
Study: 31033008

Group type: EXPERIMENTAL
Intervention: Preoperative Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 29909374

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Command Hallucinations (CTCH)
Number of subjects: 98
Study: 27688717

Group type: EXPERIMENTAL
Intervention: HealthyActions intervention group
Number of subjects: 1052
Study: 24346114

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (0.45 mg/kg, per os)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23443332

Group type: COMPARATOR
Intervention: Resistance training with placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training with glucosamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training with NSAID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training overall
Number of subjects: 0
Study: 21157050

Group type: EXPERIMENTAL
Intervention: Probiotic mouth rinse
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Number of subjects: 45
Study: 18815960

Group type: EXPERIMENTAL
Intervention: Relationship-facilitating interventions (empathy, positive regard)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment-oriented interventions (relational reframes, addressing core relational themes, highlighting vulnerable emotions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison interventions
Number of subjects: 0
Study: 16802248

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined EMS and Plyometric training (EPG)
Number of subjects: 40
Study: 15318495

Group type: EXPERIMENTAL
Intervention: Ceramic drip filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customary sources of drinking water (Control)
Number of subjects: 0
Study: 10940548

Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9078541

Group type: EXPERIMENTAL
Intervention: Glutamine (0.2 g.kg‐1.d‐1 on the day of the study) supplemented formula
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hypocaloric, enteral preterm formula alone
Number of subjects: 11
Study: 8104348

Group type: EXPERIMENTAL
Intervention: 15 mg haloperidol i.v. for 3 days followed by 3 x 5 mg haloperidol p.o./d
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3 x 100 mg perazin p.o./d
Number of subjects: 50
Study: 3743144

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo bronchodilator
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled fenoterol and placebo
Number of subjects: 12
Study: 30419088

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 268
Study: 30172363

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 739
Study: 26125285

Group type: EXPERIMENTAL
Intervention: Fixed combination of soy isoflavones (60 mg) administered concomitantly with levothyroxine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levothyroxine administered 6 hours after soy isoflavones
Number of subjects: 12
Study: 25348002

Group type: EXPERIMENTAL
Intervention: SC-PEG2500
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: SC-PEG
Number of subjects: 165

Group type: COMPARATOR
Intervention: SS-PEG2500
Number of subjects: 165
Study: 23147689

Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB) therapy for 12 weeks
Number of subjects: 30
Study: 20879881

Group type: EXPERIMENTAL
Intervention: Immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 with GM-CSF and interleukin-2)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard therapy (six cycles of isotretinoin)
Number of subjects: 226
Study: 18575771

Group type: EXPERIMENTAL
Intervention: Topical sucralfate (SUC‐LIS 95) applied daily for a median period of 42.0 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical sucralfate (SUC‐LIS 95)
Number of subjects: 50
Study: 16019690

Group type: EXPERIMENTAL
Intervention: High vitamin C levels
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: High vitamin E levels
Number of subjects: 1020
Study: 12446075

Group type: EXPERIMENTAL
Intervention: FilterWire EX distal protection system
Number of subjects: 278
Study: 11409190

Group type: EXPERIMENTAL
Intervention: Fluoxetine drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed fluoxetine capsules
Number of subjects: 0
Study: 9107582

Group type: EXPERIMENTAL
Intervention: LT02 SWL
Number of subjects: 1363

Group type: COMPARATOR
Intervention: LT01 SWL
Number of subjects: 1363
Study: 8210919

Group type: EXPERIMENTAL
Intervention: etodolac SR 400 mg once daily (q.d.)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: etodolac SR 600 mg once daily (q.d.)
Number of subjects: 404

Group type: COMPARATOR
Intervention: etodolac 200 mg twice daily (b.i.d.)
Number of subjects: 404

Group type: COMPARATOR
Intervention: etodolac 300 mg twice daily (b.i.d.)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: etodolac SR
Number of subjects: 404

Group type: COMPARATOR
Intervention: conventional etodolac
Number of subjects: 404
Study: 3513715

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 2 mg/kg/day in two divided doses for five days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 38
Study: 31272216

Group type: EXPERIMENTAL
Intervention: High-density suture spacing (approximately 5 mm apart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-density suture spacing (approximately 10 mm apart)
Number of subjects: 0
Study: 28301043

Group type: EXPERIMENTAL
Intervention: Topical Treatment Optimization Programme (TTOP)
Number of subjects: 1790

Group type: COMPARATOR
Intervention: Standard of care (non-TTOP)
Number of subjects: 1790
Study: 26214440

Group type: EXPERIMENTAL
Intervention: RFT at 70°C with PRF (42°C, 2 Hz, 240 s)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RFT at 75°C with PRF (42°C, 2 Hz, 240 s)
Number of subjects: 80

Group type: COMPARATOR
Intervention: RFT at 75°C without PRF
Number of subjects: 80

Group type: COMPARATOR
Intervention: RFT at 70°C without PRF
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined RFT and PRF
Number of subjects: 80
Study: 23784346

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 500 mg oral single dose
Number of subjects: 14
Study: 21690118

Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight loss treatment (FBT)
Number of subjects: 204
Study: 19559476

Group type: COMPARATOR
Intervention: Eflornithine (400 mg/kg per day, every 6 h) for 14 days
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (NECT): Eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral Nifurtimox (15 mg/kg per day, every 8 h) for 10 days
Number of subjects: 287

Group type: COMPARATOR
Intervention: Eflornithine
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: NECT
Number of subjects: 287
Study: 16750298

Group type: EXPERIMENTAL
Intervention: Chronic back pain patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 15129707

Group type: EXPERIMENTAL
Intervention: Gated SPET
Number of subjects: 78
Study: 11063062

Group type: EXPERIMENTAL
Intervention: Brief 7-item questionnaire screener
Number of subjects: 178

Group type: COMPARATOR
Intervention: In-depth computerized assessment administered by an interviewer
Number of subjects: 178

Group type: COMPARATOR
Intervention: Self-administered audio-computer assisted interview
Number of subjects: 178
Study: 9284898

Group type: EXPERIMENTAL
Intervention: L-arginine (0.5 g/min in the last 60 minutes of the clamp)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-arginine (0.5 g/min in the last 60 minutes of the clamp)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline 0.9% NaCl
Number of subjects: 12
Study: 7951278

Group type: EXPERIMENTAL
Intervention: Analgesic 1 at two dosage levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analgesic 2 at two dosage levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3300436

Group type: EXPERIMENTAL
Intervention: Nebulized bitolterol solution, 2.5 mg three times a day for 1 month
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nebulized isoproterenol solution, 2.5 mg three times a day for 1 month
Number of subjects: 130
Study: 30273922

Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening program (3 times weekly)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No attention control group
Number of subjects: 30
Study: 28536027

Group type: EXPERIMENTAL
Intervention: BRV-TV
Number of subjects: 1182

Group type: COMPARATOR
Intervention: RV5
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1182
Study: 25677679

Group type: EXPERIMENTAL
Intervention: QVA149 110/50 µg once daily
Number of subjects: 934

Group type: COMPARATOR
Intervention: TIO 18 µg once daily + FOR 12 µg twice daily
Number of subjects: 934
Study: 23305631

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg plus DMARDs
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo plus DMARDs
Number of subjects: 62
Study: 22124039

Group type: EXPERIMENTAL
Intervention: Non-invasive alternating current stimulation (ACS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 22
Study: 18343646

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (SFC) 50/250 microg
Number of subjects: 20
Study: 15961340

Group type: EXPERIMENTAL
Intervention: Genetic Proportional Integral Derivative Controller (GPIDC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Genetic Fuzzy Logic Controller (GFLC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual Control
Number of subjects: 12
Study: 14633181

Group type: EXPERIMENTAL
Intervention: Induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily for 8 weeks
Number of subjects: 454

Group type: COMPARATOR
Intervention: Standard treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for 8 weeks
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Both arms received ribavirin (1000-1200 mg orally per day) starting at week 4
Number of subjects: 454
Study: 10710017

Group type: EXPERIMENTAL
Intervention: Targeted decrease in sedentary behaviors
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Targeted increase in physical activity
Number of subjects: 90
Study: 9154538

Group type: COMPARATOR
Intervention: Original formulation of amoxicillin/clavulanate potassium (Augmentin) administered tid for 10 days (40/10 mg/kg/day)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: New formulation of amoxicillin/clavulanate potassium (Augmentin) administered bid for 10 days (45/6.4 mg/kg/day)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: New formulation of amoxicillin/clavulanate potassium (Augmentin) administered bid for 5 days (45/6.4 mg/kg/day)
Number of subjects: 868
Study: 8587702

Group type: COMPARATOR
Intervention: 0.65 g/kg alcohol
Number of subjects: 0
Study: 2670309

Group type: EXPERIMENTAL
Intervention: Plain tablets of pyronaridine (0.5 g on day 1, 0.3 g on day 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Enteric-coated tablets of pyronaridine (0.4 g x 2 on day 1, 0.4 g on day 2)
Number of subjects: 64
Study: 779663

Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg capsules
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31896134

Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Measurement error term included in models
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models
Number of subjects: 60
Study: 31277832

Group type: EXPERIMENTAL
Intervention: SF‐6Dv2SF‐36 (full questionnaire with 36 items)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: SF‐6Dv2ind‐10 (subset questionnaire with 10 items)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: SF‐6Dv2ind‐6 (independent instrument with 6 items)
Number of subjects: 782
Study: 28324167

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg subcutaneous injection every 4 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 144
Study: 25387762

Group type: EXPERIMENTAL
Intervention: High trust in decision-making authorities
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low trust in decision-making authorities
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Experience of outcome and procedural fairness
Number of subjects: 3
Study: 24375468

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resistance Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 0
Study: 22149065

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (800 IU) and Calcium (2 g)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Vitamin D3 (800 IU)
Number of subjects: 85
Study: 18495735

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 6 weeks through week 96
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Infliximab 7.5 mg/kg (after dose escalation starting at week 36)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 279
Study: 17459557

Group type: COMPARATOR
Intervention: Unmodified acidic soft drink
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Experimental acidic soft drink with 0.02% polyphosphate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Experimental acidic soft drink with 0.02% polyphosphate and 0.01% calcium
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Experimental acidic soft drink with 0.02% polyphosphate and 0.03% xanthan gum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mineral water
Number of subjects: 15
Study: 16343085

Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 170

Group type: COMPARATOR
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 170
Study: 12475462

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9666876

Group type: COMPARATOR
Intervention: CBZ alone (n = 23)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CBZ + T3 (n = 19)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CBZ + Triac (n = 24)
Number of subjects: 66
Study: 8944402

Group type: EXPERIMENTAL
Intervention: alprazolam (0.5 and 1 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: alprazolam (1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: alprazolam (1 mg) and lorazepam (2 mg)
Number of subjects: 12
Study: 1956688

Group type: EXPERIMENTAL
Intervention: sulphate quinine (30 mg/kg bw/day in three divided doses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: fansidar (sulphadoxine 20-30 mg/kg bw/day, single dose)
Number of subjects: 65
Study: 6111670

Group type: EXPERIMENTAL
Intervention: Cefazolin (5 days of antibiotic prophylaxis, starting just before surgery)
Number of subjects: 2137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2137
Study: 30900195

Group type: EXPERIMENTAL
Intervention: Adapted virtual mind–body group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment group (control)
Number of subjects: 0
Study: 30676542

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (TFP) 25 μg/h applied 14 hours before operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous continuous fentanyl (25 μg/h) with loading dose (25 μg) in control group
Number of subjects: 60
Study: 27923167

Group type: EXPERIMENTAL
Intervention: Running 2.0 V‐Lock™ (Arm 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0 Vicryl™ figure‐of‐eight (Arm 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Running 0 Vicryl™ with Lapra‐Ty® (Arm 3)
Number of subjects: 90
Study: 25958101

Group type: EXPERIMENTAL
Intervention: Fibrinolytic group (streptokinase 250,000 IU in 50 ml saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fibrinolytic group (streptokinase)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (50 ml saline)
Number of subjects: 40
Study: 23648056

Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine (3mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine (1.5mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21741748

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic salpingectomy (SPLS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laparoscopic salpingectomy
Number of subjects: 60
Study: 19070841

Group type: EXPERIMENTAL
Intervention: Upper-limb immobilisation (lightweight below-elbow cast with thumb free)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Right-arm immobilisation
Number of subjects: 8

Group type: COMPARATOR
Intervention: No immobilisation (unrestricted driving)
Number of subjects: 8
Study: 16988629

Group type: EXPERIMENTAL
Intervention: Insert protocol (atropine 1%, diclofenac 0.1% collyrium and Mydriasert)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Drop protocol (atropine 1%, diclofenac 0.1%, tropicamide 0.5%, and phenylephrine 10% collyrium)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Insert protocol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Drop protocol
Number of subjects: 51
Study: 15316580

Group type: EXPERIMENTAL
Intervention: (131)I alone
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: MMI stopped 7 days before (131)I
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: MMI until (131)I application
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (MMI pretreated)
Number of subjects: 187
Study: 10945550

Group type: EXPERIMENTAL
Intervention: Cholecystocholangiography (CCC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cystic duct cholangiography (CDC)
Number of subjects: 76